Document:

Exhibit 10.1

 

FIRST AMENDMENT TO 

AMENDED AND RESTATED EMPLOYMENT AGREEMENT

 

This First Amendment to Amended and Restated Employment
Agreement (this “First Amendment”) is dated as of September 23, 2022 (the “First Amendment Effective Date”), between
Blueprint Medicines Corporation, a Delaware corporation (the “Company”), and Kathryn Haviland (the “Executive”).
Capitalized terms used and not defined herein shall have the meanings ascribed to such terms in the Employment Agreement (as defined below).

 

WHEREAS, the Company and the Executive are parties
to the Amended and Restated Employment Agreement dated as of January 4, 2022 and effective as of April 4, 2022 (the “Employment
Agreement”); and

 

WHEREAS, the Company and the Executive desire to
amend the Employment Agreement as set forth below;

 

NOW, THEREFORE, for good and valuable consideration,
the receipt of which is hereby confirmed, the Company and the Executive agree that the Employment Agreement is amended as follows:

 

1.            
Section 2(c) of the Employment Agreement shall be amended and restated as follows:

 

“Incentive Compensation. During the
Term, the Executive shall be eligible to earn cash incentive compensation as determined by the Board or the Compensation Committee from
time to time. More specifically:

 

(i)           
Effective as of April 4, 2022, Executive’s target annual incentive compensation shall be 70% of the Base Salary, subject
to upward but not downward adjustment (except in connection with a proportional reduction in compensation to all or substantially all
of the Company’s employees). The Board or Compensation Committee shall weigh its bonus determination as follows: 100% on Company
performance and 0% on Executive’s individual performance, subject to adjustment as determined by the Board or the Compensation Committee
from time to time.

 

(ii)          
For the period of January 1, 2022 through April 3, 2022, the Executive is eligible to earn prorated incentive compensation
under the Original Employment Agreement in connection with her services as Chief Operating Officer of the Company during such period,
as determined by the Board or the Compensation Committee based on the Executive’s target annual incentive compensation equal to
60% of her annual base salary as in effect during such period (and the Board or the Compensation Committee shall weigh its bonus determination 75%
on Company performance and 25% on the Executive’s individual performance), provided the Executive remains employed by the Company
on the day such incentive compensation is paid.

 

(iii)         The
Executive’s target annual incentive compensation in effect at any given time is referred to herein as “Target Incentive
Compensation”; provided, that, for purposes of Section 5 hereof “Target Incentive Compensation” shall mean the
Executive’s target annual incentive compensation then in effect or, if higher, in effect immediately prior to the Sale Event,
and shall be applied to the Base Salary described in such section. To earn incentive compensation, the Executive must remain
employed by the Company in good standing through the date such incentive compensation is paid.”

 

    - 1 -

     

    

 

2.            
The Executive hereby gives express written consent in this First Amendment for the changes described herein. Accordingly, the Executive
acknowledges and agrees that the changes described herein shall not be the basis of a “Good Reason” trigger as defined in
the Employment Agreement, and therefore the Executive shall not be eligible to resign for Good Reason as a result of any such changes
or in connection with this First Amendment.

 

3.            
To the extent that there is any inconsistency between the terms and conditions of this First Amendment and the terms and conditions
of the Employment Agreement, the terms and conditions of this First Amendment shall prevail.

 

4.            
This First Amendment may be executed in any number of counterparts, each of which when so executed and delivered shall be taken
to be an original, but such counterparts shall together constitute one and the same document. Counterparts may be delivered via facsimile,
electronic mail (including pdf or any electronic signature complying with the U.S. Federal ESIGN Act of 2000) or other transmission method,
and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

 

5.            
Except as amended hereby, the Employment Agreement remains in full force and effect and, as amended hereby, the Employment Agreement
represents the entire agreement between the Executive and the Company, and there are no other agreements, written or oral, relating to
the subject matter hereof. On and after the First Amendment Effective Date, all references in the Employment Agreement to “this
Agreement” (including “hereof,” “herein” and similar words or phrases) shall mean the Employment Agreement,
as amended by this First Amendment.

 

IN WITNESS WHEREOF, the undersigned have executed
this First Amendment as of the date first written above.

 

	 	BLUEPRINT MEDICINES CORPORATION
	 	 	 
	 	By:	/s/ Tracey McCain
	 	Name:	Tracey McCain
	 	Title:	Executive Vice President, Chief Legal and Compliance Officer
	 	 
	 	EXECUTIVE
	 	 
	 	/s/ Kathryn Haviland 
	 	Kathryn Haviland

 

    - 2 -Exhibit 10.2

 

THIRD AMENDMENT TO EMPLOYMENT AGREEMENT

 

This Third Amendment to Employment Agreement (this
 “Third Amendment”) is dated as of September 23, 2022 (the “Third Amendment Effective Date”), between Blueprint
Medicines Corporation, a Delaware corporation (the “Company”), and Michael Landsittel (the “Executive”). Capitalized
terms used and not defined herein shall have the meanings ascribed to such terms in the Employment Agreement (as defined below).

 

WHEREAS, the Company and the Executive are parties
to the Employment Agreement dated as of November 22, 2017, as amended by the First Amendment to Employment Agreement dated as of January
30, 2019, and as further amended by the Second Amendment to Employment Agreement dated as of December 22, 2021 (collectively, the “Employment
Agreement”); and

 

WHEREAS, the Company and the Executive desire to
amend the Employment Agreement as set forth below;

 

NOW, THEREFORE, for good and valuable consideration,
the receipt of which is hereby confirmed, the Company and the Executive agree that the Employment Agreement is amended as follows:

 

1.            
Section 2(b) of the Employment Agreement shall be amended and restated as follows:

 

“Incentive Compensation. During the
Term, the Executive shall be eligible to earn cash incentive compensation as determined by the Board or the Compensation Committee from
time to time. Effective as of January 1, 2022, Executive’s target annual incentive compensation shall be 50% of the Base Salary,
subject to upward but not downward adjustment (except in connection with a proportional reduction in compensation to all or substantially
all of the Company’s employees). The Board or Compensation Committee shall weigh its bonus determination as follows: 75% on Company
performance and 25% on Executive’s individual performance, subject to adjustment as determined by the Board or the Compensation
Committee from time to time. The Executive’s target annual incentive compensation in effect at any given time is referred to herein
as “Target Incentive Compensation,” except for purposes of Section 5 hereof, where “Target Incentive Compensation”
shall mean the target annual incentive compensation then in effect, or if higher, in effect immediately prior to the Sale Event. To earn
incentive compensation, the Executive must remain employed by the Company in good standing through the date such incentive compensation
is paid.”

 

2.            
The Executive hereby gives express written consent in this Third Amendment for the changes described herein. Accordingly, the Executive
acknowledges and agrees that the changes described herein shall not be the basis of a “Good Reason” trigger as defined in
the Employment Agreement, and therefore the Executive shall not be eligible to resign for Good Reason as a result of any such changes
or in connection with this Third Amendment.

 

    - 1 -

     

    

 

3.                 
 To the extent that there is any inconsistency between the terms and conditions of this Third Amendment and the terms and conditions
of the Employment Agreement, the terms and conditions of this Third Amendment shall prevail.

 

4.                 
This Third Amendment may be executed in any number of counterparts, each of which when so executed and delivered shall be taken
to be an original, but such counterparts shall together constitute one and the same document. Counterparts may be delivered via facsimile,
electronic mail (including pdf or any electronic signature complying with the U.S. Federal ESIGN Act of 2000) or other transmission method,
and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

 

5.                 
Except as amended hereby, the Employment Agreement remains in full force and effect and, as amended hereby, the Employment Agreement
represents the entire agreement between the Executive and the Company, and there are no other agreements, written or oral, relating to
the subject matter hereof. On and after the Third Amendment Effective Date, all references in the Employment Agreement to “this
Agreement” (including “hereof,” “herein” and similar words or phrases) shall mean the Employment Agreement,
as amended by this Third Amendment.

 

IN WITNESS WHEREOF, the undersigned have executed
this Third Amendment as of the date first written above.

 

	 	BLUEPRINT MEDICINES CORPORATION
	 	 	 
	 	By:	/s/ Kathryn Haviland
	 	Name:	Kathryn Haviland
	 	Title:	President and Chief Executive Officer
	 	 
	 	EXECUTIVE
	 	 
	 	/s/ Michael Landsittel
	 	Michael Landsittel

 

    - 2 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}]]